Top Markets
Coin of the day
Rafael Holdings, Inc. Rafael Holdings, Inc.

Rafael Holdings, Inc.

RFL
Rang in Aktien #21321
Rafael Holdings, Inc. holds strategic investments in both early-stage and... Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Aktienkurs
$2.15
Zuletzt synchronisiert: 2026-08-21
Marktkapitalisierung
$110.06M
Veränderung (1 Tag)
13.46%
Veränderung (1 Jahr)
37.76%
Land
US
Handel Rafael Holdings, Inc. (RFL)

Kategorie

EPS für Rafael Holdings, Inc. (RFL)
EPS zum 2026 TTM: 0
Laut den aktuellen Finanzberichten und dem Aktienkurs von Rafael Holdings, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) 0. Am Ende des Jahres 2026 betrug das EPS 0 gleich wie dem EPS von 2026, das 0 betrug.
EPS-Verlauf von Rafael Holdings, Inc. von 2026 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
Nicht genügend Daten für die angegebenen Daten.
EPS für ähnliche Unternehmen oder Wettbewerber
Unternehmen EPS EPS-Differenz Land
$4.39 -
US
- -
DE
$0.44 -
CN
- -
DE
$21.29 -
US